Show stories from Brazil Latin America

News from aidsmap

  • MTCT programmes short-sighted if no long-term HIV drugs for mums

    Keith Alcorn | 05 April 2002

    Treatment programmes which use antiretrovirals to prevent mother to child transmission are likely to succeed only in creating a generation of orphans and ruining the treatment chances of mothers, according ...

  • First unequivocal case of HIV superinfection

    Robert Fieldhouse | 03 March 2002

    Last week, at the Ninth Retroviruses Conference in Seattle, researchers from the University of Geneva, Switzerland presented a case study of a 38 year old gay man who has been ...

  • South African activists challenge state on generics

    Michael Carter | 30 January 2002

    Further confrontation between treatment activists and the South African government looks inevitable, after members of the Treatments Action Campaign (TAC) and the Congress of South African Trade Unions imported cheap ...

  • Global Fund to make first grants in April

    Julian Meldrum | 29 January 2002

    The first directors have now been appointed to the Global Fund to fight AIDS, TB and Malaria, which has just finished its first meeting in Geneva, Switzerland. Funding criteria have ...

  • Community REACH grants available for Africa, Asia, Americas and Eastern Europe?

    Julian Meldrum | 14 January 2002

    A US-government backed grants programme called Community REACH (Rapid and Effective Action Combating HIV/AIDS) was launched on 7 January with a Request For Applications to support work on HIV ...

  • Tuberculosis now has babies

    Julian Meldrum | 13 December 2001

    The final day of the 12th ICASA in Burkina Faso heard a plenary presentation from Dr Joseph Odhiambo, from Nairobi, Kenya, on tuberculosis and HIV. After a brief global overview he ...

  • Patents deal may benefit few

    Michael Carter | 21 November 2001

    Last week¹s deal allowing developing countries to make generic versions of antiretrovirals may, in reality do little to increase their availability, as the countries which need them most lack the ...

  • Tipranavir development plans announced

    Keith Alcorn | 19 November 2001

    Boehringer-Ingelheim has announced further development plans for its protease inhibitor, tipranavir. Speaking at NAM’s symposium on Emerging Therapies for HIV Infection last Friday at the Royal College of Physicians in London, Dr ...

Editors’ picks from other sources

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.